Composition: Losartan Potassium + Amlodipine Besylate (equivalent to Amlodipine)
Strengths: 50 mg/5 mg, 100 mg/5 mg, 50 mg/10 mg (as described; confirm commercial availability)
Usage: Management of high blood pressure (hypertension)
Category: Antihypertensive / Cardiovascular Medicines
Therapeutic category: ARB + Calcium Channel Blocker
SKU: Losartan Potassium Amlodipine Besylate Tablets
Categories: Tablets Manufacturer
Yes! I am InterestedWhatsAppLosartan Potassium & Amlodipine Besylate Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (certification status to be verified)
Exported by: Healthy Inc (export credentials to be verified)
Losartan Potassium and Amlodipine Besylate Tablets combine two medicines used to manage hypertension. Losartan is an angiotensin II receptor blocker (ARB), while amlodipine is a dihydropyridine calcium channel blocker (CCB). Their complementary mechanisms can help control blood pressure when a clinician determines combination therapy is appropriate.
Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter in the supplied product information. Manufacturing approvals, site certification, market authorization and actual availability should be confirmed with current documents before procurement or publication.
| Product Name | Losartan Potassium & Amlodipine Besylate Tablets |
|---|---|
| Composition / Strengths | Losartan Potassium 50 mg + Amlodipine 5 mg; Losartan Potassium 100 mg + Amlodipine 5 mg; Losartan Potassium 50 mg + Amlodipine 10 mg (amlodipine amount expressed as base equivalent from amlodipine besylate) |
| Dosage Form | Oral tablet; film coating and appearance subject to approved product specification |
| Therapeutic Class | Antihypertensive: ARB + CCB fixed-dose combination |
| Indication | Hypertension, where this combination is authorized and prescribed |
| Pharmacopoeial Standard | IP / BP / USP claims require product-specific verification |
| Packaging | Blisters or bottles, subject to confirmed commercial specification |
| Shelf Life | Per approved stability data and product label; not independently verified |
Developing a combination tablet requires compatible excipients, controlled mixing, uniformity of both active ingredients, dissolution testing, and protection from moisture and light where supported by stability studies. The proposed bilayer or conventional tablet design, packaging barrier, and manufacturing process must be validated for the actual marketed product.
Losartan-containing products may require risk-based assessment and control of nitrosamine impurities under applicable regulatory requirements. No claim of being completely “nitrosamine-free” should be made without supporting analytical evidence.
Relevant quality controls include identity, assay, content uniformity, dissolution for each active ingredient, related substances, nitrosamine risk assessment, packaging integrity, and stability. Acceptance criteria must follow the approved product specification and applicable pharmacopoeial or regulatory requirements; fixed numerical limits cannot be assumed for every market.
Losartan: blocks the angiotensin II AT1 receptor, reducing vasoconstriction and aldosterone-mediated effects. Amlodipine: inhibits calcium entry into vascular smooth muscle, promoting arterial relaxation. Together, they may improve blood-pressure control compared with an insufficient single-agent regimen.
Use depends on local approval, patient characteristics, and clinician assessment. Peripheral edema associated with amlodipine can still occur; any reduction with combination therapy is not guaranteed.
For export or contract manufacturing enquiries, request current manufacturing licences, GMP evidence, product registration status, Certificate of Analysis, stability data, packaging specifications, and CTD/ACTD dossier availability as applicable. Certificate of Pharmaceutical Product, Free Sale Certificate, and market-specific import permissions should be verified before making commitments.
Q: What is this combination used for?
A: Treatment of hypertension when a prescriber considers the two-drug combination suitable.
Q: Is this the same as taking two separate tablets?
A: It contains the same classes of active medicines at specified doses, but switching products should be directed by a clinician; bioequivalence cannot be assumed without product-specific evidence.
Q: Can it cause ankle swelling?
A: Yes. Amlodipine can cause peripheral edema even in combination tablets.
Q: Can it be taken during pregnancy?
A: No. Losartan can cause fetal injury; contact a clinician immediately if pregnancy is suspected or confirmed.
Strength and dosing schedule must be selected by the prescribing clinician based on blood-pressure response, previous therapy, kidney and liver function, and the approved local label. Do not change strength, double doses, or discontinue treatment without medical advice. Tablets are generally taken consistently at the same time each day; follow the product-specific instructions.
Possible adverse effects include dizziness, headache, low blood pressure, and ankle swelling. Losartan may increase potassium levels and affect kidney function; blood pressure, serum potassium, and renal function may need monitoring. Important interactions include potassium supplements, potassium-sparing diuretics, certain anti-inflammatory drugs, and other blood-pressure medicines. Pregnancy warning: medicines acting on the renin–angiotensin system can injure or kill a developing fetus. Seek immediate medical advice if pregnancy occurs.
Store in the original container according to the approved pack label, protected from excess moisture and light as directed. The proposed storage limit of below 25°C and shelf life of 24–36 months must be confirmed against product-specific stability data. Keep out of reach of children.